One stock that might be an intriguing choice for investors right now is BioTime, Inc. BTX. This is because this security in the Medical-Biomedical/Genetics space is seeing solid earnings estimate ...

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced it is ...

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver ...

BioTime, Inc. (NYSE: BTX) is a clinical-stage biotechnology company focused on regenerative medicine and pluripotent stem cell technologies. It was established by Dr. Michael D. West, the original ...

BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced ™Portal Offering Additional ™ Human Progenitor Cells Including Those for Diabetes Research BioTime, Inc. (NYSE MKT: BTX) and ...

BioTime has appointed Brian Culley to serve as its sole CEO, as part of a corporate restructuring executed by the board of directors. Culley takes over for co-CEOs Adi Mohanty and Michael West, ...

BioTime, Inc.Peter Garcia, 510-521-3390, ext 367Chief Financial OfficerorJudith Segall, 510-521-3390, ext 301orLifeMap Sciences, Inc.Kenneth Elsner, 781-826-7719COO BioTime, Inc. (NYSE MKT: BTX) and ...

Company will merge Xennex into LifeMap Sciences subsidiary. BioTime is to acquire Xennex to take over the latters’ global marketing rights to the GeneCards® and PanDaTox® databases. BioTime says it ...

The muscle cell lines will display the genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal muscular atrophy Type I, facioscapulohumeral muscular dystrophy 1A, and Becker ...

Geron's stem cell assets were given a new lease in early January when former CEO Tom Okarma, now heading a subsidiary of BioTime of Alameda, California, signed a definitive agreement for the latter to ...